Navigation Links
PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
Date:3/22/2010

2';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.pharmathene.com/">www.pharmathene.com.  A link to the webcast may be found under the Investor Relations section of the website.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia(R) - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

For more information about PharmAthene, please visit

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
2. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
3. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
4. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
5. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
6. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
7. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
8. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
9. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
10. PharmAthene Reports Second Quarter 2009 Financial and Operational Results
11. PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) ... report "Cell Therapy - Technologies, Markets and ... report describes and evaluates cell therapy technologies and ... important role in the practice of medicine. Hematopoietic ... bone marrow transplants. Role of cells in drug ...
(Date:5/28/2015)... CARLOS, Calif. , May 28, 2015 /PRNewswire/ ... testing, today announced a study published in ... the Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal test ... the first trimester. A study ... that complete molar pregnancies occur in about 1 ...
(Date:5/28/2015)... , May 28, 2015 RXi Pharmaceuticals Corporation ... discovering and developing innovative therapeutics, primarily in the areas ... a public offering of 26 million units at a ... gross proceeds of approximately $10.4 million. Each unit consists ... 13-month overallotment purchase right to purchase 0.50 of a ...
(Date:5/28/2015)... 2015 The Fertility Centers of New ... Danielle Vitiello has taken on a new and expanded ... will provide guidance, leadership, oversight and quality assurance for ... Vitiello among our team of experienced reproductive endocrinologists,” said ... A. Hill, M.D. “Her expertise and compassionate, individualized care ...
Breaking Biology Technology:Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... MedCap press releases contain false and misleading ... 25 /PRNewswire-FirstCall/-- VaxGen,Inc. (OTC Bulletin Board: VXGN.OB), ... ), Dear Stockholders, On March ... stockholder in,VaxGen, issued a press release entitled ...
... BEIJING, March 25 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), ... that its,Annual General Meeting originally scheduled for March 25, ... the March 25, 2008 Annual General Meeting, the required ... present. In accordance with,Antigua law, the meeting is adjourned ...
... N.J., March 24 Osteotech, Inc.,(Nasdaq: OSTE ... biologic solutions for,regenerative medicine, announced today that the ... validity of its U.S. Patent No.,5,676,146. The ,146 ... demineralized bone, with a radiopaque material, such as ...
Cached Biology Technology:VaxGen Issues Rebuttal to MedCap Letter 2VaxGen Issues Rebuttal to MedCap Letter 3VaxGen Issues Rebuttal to MedCap Letter 4VaxGen Issues Rebuttal to MedCap Letter 5VaxGen Issues Rebuttal to MedCap Letter 6VaxGen Issues Rebuttal to MedCap Letter 7VaxGen Issues Rebuttal to MedCap Letter 8VaxGen Issues Rebuttal to MedCap Letter 9VaxGen Issues Rebuttal to MedCap Letter 10VaxGen Issues Rebuttal to MedCap Letter 11Sinovac Announces Adjournment of Annual General Meeting 2U.S. Patent Office Confirms Validity of Osteotech's U.S. Patent No. 5,676,146 2
(Date:5/21/2015)... 21, 2015 According to ... Solutions (Hardware, Software, Services), by Applications (Surveillance (Airborne, ... by End-Users (Military & Defense & Commercial) - ... Imaging Market is expected to grow from $7252.0 ... at a Compound Annual Growth Rate (CAGR) of ...
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/19/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... research team has developed a process that removes a ... team has programmed a photosynthetic microbe to self-destruct, making ... potentially less costly. "The real costs involved ... turning them into fuel," said Roy Curtiss, director of ...
... , TORONTO, Dec. 7 ... the assets of the healthcare communications company previously operating as ... move forward under new leadership and funding. , IgeaCare Solutions ... Chief Executive Officer. Under his direction, the new company will ...
... air and water pollution along the Athabasca River and ... say pollution levels have increased as a direct result ... biological sciences professor David Schindler was part of the ... study and found high levels of Polycyclic Aromatic Compounds. ...
Cached Biology News:Self-destructing bacteria improve renewable biofuel production 2Self-destructing bacteria improve renewable biofuel production 3IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2
... PDS-1000 He biolistic system enables 7-10 times more ... It fits into the shocking chamber of the ... shock wave over 7 microcarriers. By uniformly spreading ... larger area, the system maximizes the number of ...
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
... mitochondrial transmembrane potential is one of ... following induction of apoptosis. The ... lipophilic cation, termed as MitoLight, as ... a mitochondrial dye that stains mitochondria ...
Liquid. 50 μg/ml in PBS, pH 7.4. PROTECT FROM LIGHT. A convenient form of propidium iodide useful for flow cytometry studies. RTECS SF7949600, CAS 25535-16-4, M.W. 668.4. ...
Biology Products: